NYSE:PEN - New York Stock Exchange, Inc. - US70975L1070 - Common Stock - Currency: USD
289.25
-2.71 (-0.93%)
The current stock price of PEN is 289.25 USD. In the past month the price increased by 13.07%. In the past year, price increased by 36.26%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.02 | 232.31B | ||
ISRG | INTUITIVE SURGICAL INC | 70.18 | 192.17B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.81 | 155.01B | ||
SYK | STRYKER CORP | 30.65 | 146.59B | ||
MDT | MEDTRONIC PLC | 15.57 | 106.66B | ||
BDX | BECTON DICKINSON AND CO | 11.86 | 47.99B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.86 | 44.12B | ||
IDXX | IDEXX LABORATORIES INC | 42.69 | 39.43B | ||
RMD | RESMED INC | 26.95 | 35.88B | ||
DXCM | DEXCOM INC | 50.52 | 32.68B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.96 | 31.51B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.51 | 22.46B |
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4500
Phone: 15109952486
The current stock price of PEN is 289.25 USD. The price decreased by -0.93% in the last trading session.
The exchange symbol of PENUMBRA INC is PEN and it is listed on the New York Stock Exchange, Inc. exchange.
PEN stock is listed on the New York Stock Exchange, Inc. exchange.
24 analysts have analysed PEN and the average price target is 314.46 USD. This implies a price increase of 8.72% is expected in the next year compared to the current price of 289.25. Check the PENUMBRA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PENUMBRA INC (PEN) has a market capitalization of 11.20B USD. This makes PEN a Large Cap stock.
PENUMBRA INC (PEN) currently has 4500 employees.
PENUMBRA INC (PEN) has a support level at 278.4 and a resistance level at 299.79. Check the full technical report for a detailed analysis of PEN support and resistance levels.
The Revenue of PENUMBRA INC (PEN) is expected to grow by 13.47% in the next year. Check the estimates tab for more information on the PEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PEN does not pay a dividend.
PENUMBRA INC (PEN) will report earnings on 2025-07-28, after the market close.
The PE ratio for PENUMBRA INC (PEN) is 87.92. This is based on the reported non-GAAP earnings per share of 3.29 and the current share price of 289.25 USD. Check the full fundamental report for a full analysis of the valuation metrics for PEN.
The outstanding short interest for PENUMBRA INC (PEN) is 4.21% of its float. Check the ownership tab for more information on the PEN short interest.
ChartMill assigns a technical rating of 9 / 10 to PEN. When comparing the yearly performance of all stocks, PEN is one of the better performing stocks in the market, outperforming 92.55% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to PEN. PEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months PEN reported a non-GAAP Earnings per Share(EPS) of 3.29. The EPS increased by 44.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.41% | ||
ROA | 2.65% | ||
ROE | 3.48% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 83% to PEN. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of 28.94% and a revenue growth 13.47% for PEN